Perioperative handling of antiplatelet therapy: Watching the two sides of the coin

Internal and Emergency Medicine

Volumn 4, Issue 4, 2009, Pages 275-276

  Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ARTICLE; HUMAN; PERIOPERATIVE PERIOD;

HUMANS; PERIOPERATIVE CARE; PLATELET AGGREGATION INHIBITORS;

EID: 70350620822     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0271-2     Document Type: Article

References (15)

1. Unal B, Critchley JA, Capewell S (2004) Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109:1101-1107.
2. Ford ES, Ajani UA, Croft JB et al (2007) Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 356:2388-2398.
3. Patrono C, Garcia Rodriguez LA, Landolfi R et al (2005) Low dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383.
4. Burger W, Chemnitius JM, Kneissl GD et al (2005) Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risk after its perioperative withdrawal versus bleeding risk with its continuation-review and meta-analysis. J Intern Med 257:399-414.
5. Biondi-Zoccai GG, Lotrionte M, Agostoni P et al (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27:2667-2674.
6. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015.
7. Douketis JD, Berger PB, Dunn AS et al (2008) The perioperative management of antithrombotic therapy. Chest 133:299S-339S.
8. Di Minno MND, Prisco D, Ruocco AL et al (2009) Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med doi: 10.1007/s11739-009-0265-0.
9. Kinnaird TD, Stabile E, Mintz GS et al (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92:930-935.
10. Feit F, Voeltz MD, Attubato MJ et al (2007) Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol 100:1364-1369.
11. Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-2230.
12. Gresele P, Falcinelli E, Momi S (2008) Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 29:352-360.
13. Becker LC, Moliterno DJU, Jennings LK et al (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373:919-928.
14. Hippisley-Cox J, Coupland C (2005) Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ 330:1059-1063.
15. Bhatt DL, Steg PG, Ohman EM (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-189.